Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.
Risa M HoffmanSean BrummelLauren ZiembaLameck ChinulaKatie McCarthyLee FairliePatrick Jean-PhilippeNahida ChakhtouraBen JohnstonChelsea KrotjeTeacler G NematadziraFrances NakayiwaVictoria NdyanabangiSherika HanleyGerhard TheronAvy ViolariEsau JoãoMario Dias Correa JuniorCristina Barroso HoferOranich NavanukrohLinda AurpibulNeetal NevrekarRebecca ZashRoger ShapiroJeffrey S A StringerJudith S CurrierPaul SaxShahin Lockmannull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Antepartum weight gain on DTG regimens was protective against adverse pregnancy outcomes traditionally associated with insufficient weight gain, supportive of guidelines recommending DTG-based ART for women starting ART during pregnancy. Interventions to mitigate postpartum weight gain are needed.
Keyphrases
- weight gain
- pregnancy outcomes
- antiretroviral therapy
- hiv infected
- body mass index
- pregnant women
- birth weight
- hiv infected patients
- human immunodeficiency virus
- hiv positive
- hiv aids
- weight loss
- physical activity
- clinical practice
- emergency department
- metabolic syndrome
- type diabetes
- adverse drug
- men who have sex with men
- adipose tissue
- insulin resistance
- polycystic ovary syndrome
- smoking cessation
- preterm birth
- gestational age